Posted by Michael Wonder on 10 Jul 2017
CSL to fight patent infringement claim from US based Bioverativ
10 July 2017 - Australian vaccines and blood products developer CSL says it will vigorously fight a patent infringement claim launched by US-based biotech Bioverativ in relation to CSL’s haemophilia B drug, Idelvion.
Bioverativ, which develops treatments for haemophilia and other rare blood disorders, has filed complaints in the US District Court for the District of Delaware and with the International Trade Commission.
Bioverativ claims that Idelvion infringes three Bioverativ patents. “CSL is highly confident of its intellectual property position for Idelvion, a product of over a decade of innovative research by CSL Behring and representative of a major advance for patients suffering haemophilia B, and will vigorously defend against the claim,” CSL said in a statement on Monday. The US Food and Drug Administration approved Idelvion in March 2016 to prevent and manage bleeding episodes in children and adults with haemophilia B. CSL said it could not provide specific details of the infringement claim because it was a litigation matter.
